|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
LT3710439T
(lt)
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
PE20260440A1
(es)
|
2018-11-09 |
2026-02-19 |
Hoffmann La Roche |
Compuestos de anillo fusionado
|
|
US20220152026A1
(en)
|
2019-02-12 |
2022-05-19 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
|
KR102934231B1
(ko)
|
2019-03-05 |
2026-03-06 |
아스트라제네카 아베 |
항암제로 유용한 융합 삼환식 화합물
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
WO2021031952A1
(zh)
*
|
2019-08-16 |
2021-02-25 |
劲方医药科技(上海)有限公司 |
氧代六元环并嘧啶类化合物，其制法与医药上的用途
|
|
CN112390796B
(zh)
*
|
2019-08-19 |
2023-06-27 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
WO2021058018A1
(en)
*
|
2019-09-29 |
2021-04-01 |
Beigene, Ltd. |
Inhibitors of kras g12c
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CN112851663B
(zh)
*
|
2019-11-12 |
2023-07-18 |
博瑞生物医药（苏州）股份有限公司 |
一种并杂环化合物及其用途
|
|
AU2020386967A1
(en)
*
|
2019-11-22 |
2022-07-07 |
Sail Biomedicines, Inc. |
Pyridopyrimidinone derivatives as AHR antagonists
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021109737A1
(zh)
*
|
2019-12-02 |
2021-06-10 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
JP2023504623A
(ja)
*
|
2019-12-04 |
2023-02-06 |
アーカス バイオサイエンシーズ，インコーポレーテッド |
Ｈｉｆ－２アルファの阻害剤
|
|
CN113024544B
(zh)
*
|
2019-12-09 |
2024-07-02 |
武汉誉祥医药科技有限公司 |
一种含氰基并杂环化合物及其用途
|
|
EP4097092A1
(en)
|
2020-01-28 |
2022-12-07 |
Protego Biopharma, Inc. |
Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
CN113637005B
(zh)
*
|
2020-02-24 |
2024-05-24 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
JP7736700B2
(ja)
*
|
2020-02-28 |
2025-09-09 |
リミックス セラピューティクス インコーポレイテッド |
複素環アミド及びスプライシングを調節するためのその使用
|
|
CN119118872A
(zh)
|
2020-03-19 |
2024-12-13 |
艾库斯生物科学有限公司 |
作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
|
|
BR112022020965A2
(pt)
*
|
2020-04-17 |
2022-12-06 |
Dong A St Co Ltd |
Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2023544450A
(ja)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
三環式ピリドン及びピリミドン
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
JP2024501507A
(ja)
*
|
2020-12-25 |
2024-01-12 |
スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド |
ケトヘキソキナーゼ阻害剤及びその用途
|
|
WO2022152313A1
(zh)
*
|
2021-01-18 |
2022-07-21 |
成都百裕制药股份有限公司 |
嘧啶衍生物及其在医药上的应用
|
|
CN113072480B
(zh)
*
|
2021-04-13 |
2022-09-30 |
常州佳德医药科技有限公司 |
一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
BR112023024906A2
(pt)
*
|
2021-05-28 |
2024-02-15 |
Redx Pharma Plc |
Compostos
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
WO2023009585A2
(en)
|
2021-07-28 |
2023-02-02 |
Protego Biopharma, Inc. |
Transthyretin stabilizing compounds
|
|
KR20240055778A
(ko)
|
2021-09-01 |
2024-04-29 |
노파르티스 아게 |
Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US12145901B1
(en)
|
2021-09-17 |
2024-11-19 |
Arcus Biosciences, Inc. |
Process for preparing tetralin compounds
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
CA3234375A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
WO2023154124A1
(en)
*
|
2022-02-09 |
2023-08-17 |
Enliven Therapeutics, Inc. |
Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
US20260015351A1
(en)
*
|
2022-06-30 |
2026-01-15 |
Axonis Therapeutics, Inc. |
Methods and compounds for inhibiting mkk7 enzymes
|
|
EP4573095A1
(en)
|
2022-08-17 |
2025-06-25 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
CN120659773A
(zh)
|
2022-11-09 |
2025-09-16 |
锐新医药公司 |
化合物、复合物以及其制备方法和用途
|
|
TW202430179A
(zh)
|
2022-11-21 |
2024-08-01 |
美商樹線生物科學公司 |
螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
EP4721766A1
(en)
|
2023-06-02 |
2026-04-08 |
Daiichi Sankyo Company, Limited |
Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
|
|
CN121263417A
(zh)
|
2023-06-30 |
2026-01-02 |
金橘生物科技公司 |
取代的稠合三环胺化合物及其作为ras抑制剂的用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025213088A1
(en)
*
|
2024-04-05 |
2025-10-09 |
Tenvie Therapeutics, Inc. |
Compounds, compositions, and methods
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|